RT @TumorBoardTues
Set a ⏲ to join #TumorBoardTuesday on 03.14.23 at 8pm ET

Join👨🏻‍⚕️@brian_rini @JVentoMD 👨🏻‍⚕️ as they break down 📰Adjuvant treatment in #RenalCellCarcinoma

🧬 While we finalize the case, collect FREE #CME (AMA & MOC)

👉🏽http://integrityce.com/tbt 👈🏼 #OncTwitter #RenalCell

RT @TumorBoardTues
Set a ⏲ to join #TumorBoardTuesday on 03.14.23 at 8pm ET

Join👨🏻‍⚕️@brian_rini @JVentoMD 👨🏻‍⚕️ as they break down 📰Adjuvant treatment in #RenalCellCarcinoma

🧬 While we finalize the case, collect FREE #CME (AMA & MOC)

👉🏽http://integrityce.com/tbt 👈🏼 #OncTwitter #RenalCell

Set a ⏲ to join #TumorBoardTuesday on 03.14.23 at 8pm ET

Join👨🏻‍⚕️@brian_rini @JVentoMD 👨🏻‍⚕️ as they break down 📰Adjuvant treatment in #RenalCellCarcinoma

🧬 While we finalize the case, collect FREE #CME (AMA & MOC)

👉🏽http://integrityce.com/tbt 👈🏼 #OncTwitter #RenalCell

RT @JohnEbbenMDPhD
@TumorBoardTues @shilpaonc @MPishvaian @KidneyCancer_Ca @KidneyCancer @kidneycancers @brian_rini @katy_beckermann 3/5 #TumorBoardTuesday #RenalCell
Case🎀
📷 TBT in an image

We summarized our case discussion in recurrent/stage IV #RCC

Important to consider approach to tox, especially toxicities attributable to BOTH IO & VEGFR TKI‼️

‼️Involve subspecialists EARLY when tox is noted‼️

RT @JohnEbbenMDPhD
@TumorBoardTues @shilpaonc @MPishvaian @KidneyCancer_Ca @KidneyCancer @kidneycancers @brian_rini @katy_beckermann 3/5 #TumorBoardTuesday #RenalCell
Case🎀
📷 TBT in an image

We summarized our case discussion in recurrent/stage IV #RCC

Important to consider approach to tox, especially toxicities attributable to BOTH IO & VEGFR TKI‼️

‼️Involve subspecialists EARLY when tox is noted‼️

RT @JohnEbbenMDPhD
@TumorBoardTues @shilpaonc @MPishvaian @KidneyCancer_Ca @KidneyCancer @kidneycancers @brian_rini @katy_beckermann 3/5 #TumorBoardTuesday #RenalCell
Case🎀
📷 TBT in an image

We summarized our case discussion in recurrent/stage IV #RCC

Important to consider approach to tox, especially toxicities attributable to BOTH IO & VEGFR TKI‼️

‼️Involve subspecialists EARLY when tox is noted‼️

RT @JohnEbbenMDPhD
@TumorBoardTues @shilpaonc @MPishvaian @KidneyCancer_Ca @KidneyCancer @kidneycancers @brian_rini @katy_beckermann 3/5 #TumorBoardTuesday #RenalCell
Case🎀
📷 TBT in an image

We summarized our case discussion in recurrent/stage IV #RCC

Important to consider approach to tox, especially toxicities attributable to BOTH IO & VEGFR TKI‼️

‼️Involve subspecialists EARLY when tox is noted‼️

RT @shilpaonc
@TumorBoardTues @MPishvaian 1/18 #TumorBoardTuesday #RenalCancer #OncTwitter

60yo 👴🏽#RenalCell dx in 2022 tx with right radical nephrectomy
6mo f/u
Uses WC d/t DM2 - limited mobility & homebound

🤨 What would be your next step?

RT @shilpaonc
@TumorBoardTues @MPishvaian @montypal @brian_rini @DrYukselUrun @TiansterZhang @KidneyCancer @HHammersMD @arihakimi @RCCadvocate @AmandaNizamMD @QingZhangLab @DrRanaMcKay @DrScottHaake @DrDavidNanus @PavlosMsaouel @OAlhalabiMD @kcCURE @motzermd @MosheOrnsteinMD @neerajaiims @RenoHemonc @DrChoueiri 3/18 #TumorBoardTuesday #RenalCell

🤨 What factors do you take into account to decide between VEGF-TKI or IO-IO as treatment option at 1st relapse?

RT @shilpaonc
🧗🏽Summit RCC Mts🧗🏽┈┈🏔 TKI/IO safety data & AE mgmt #RenalCell🏔┈┈ w guides @shilpaonc @katy_beckermann @brian_rini ┈┈🔹#CME info 👉 http://bit.ly/3iLN6aX 👈 @BonumCe ┈┈🔸Support by edu grants from Eisai & @Merck 🔹#TumorBoardTuesday #OncTwitter https://twitter.com/i/broadcasts/1kvKpmldAEkGE

RT @shilpaonc
4/ #TumorBoardTuesday #BonumCE
#RenalCell #NephTwitter #MedTwitter

Let’s revisit efficacy of 🔑Ph3 clin trials:
💎#CLEAR
💎#KEYNOTE426
💎#CheckMate9ER
💎#CheckMate214

RT @shilpaonc
6/ #TumorBoardTuesday #OncTwitter #RenalCell #NephTwitter #MedTwitter #BonumCE
#CME 🔗http://bit.ly/3FamQyu

🔴#PostTest Q 2️⃣
🗳️ Which of the following is NOT a characteristic of immune-mediated toxicities associated with the use of ICIs?

RT @shilpaonc
7/ #TumorBoardTuesday #RenalCell #NephTwitter #MedTwitter #BonumCE
#CME 🔗http://bit.ly/3FamQyu

🔴#PostTest Q3️⃣
🗳️ Pt treated w/ combo of pembrolizumab and lenvatinib for metastatic RCC develops grade 3 diarrhea. How might you diagnose which drug is causing this toxicity?

RT @shilpaonc
8/ #TumorBoardTuesday #RenalCell #NephTwitter

🔴#PostTest Q 4️⃣
🗳️ Pt treated w/ combo of cabozantinib + nivolumab develops G3 hypertension. Cabo therapy is held & pt receives anti-hypertensive medication & BP recovers to baseline. At what dose can cabozantinib be restarted?

RT @shilpaonc
9/#TumorBoardTuesday #OncTwitter #NephTwitter #BonumCE

🏃‍♀️Need to catch up on...
🦺TKI/IO safety data
🥽Tox to look 4
⛑AE mgmt
#ICYMI 🪡#RenalCell #MedTweetorial🧵👇

https://twitter.com/TumorBoardTues/status/1602468719426342913

9/#TumorBoardTuesday #OncTwitter #NephTwitter #BonumCE

#ICYMI 🪡#RenalCell #MedTweetorial🧵
w @brian_rini @shilpaonc @katy_beckermann

🦺TKI/IO safety data
🥽Tox to look 4
⛑AE mgmt

---
RT @TumorBoardTues
1/ #OncTwitter #NephTwitter #TumorBoardTuesday
✅#RenalCell #MedTweetorial🧵
w @brian_rini @shilpaonc @katy_beckermann

🦺TKI/IO safety data
🥽Tox to look 4
⛑AE mgmt

🆓#CME @BonumCe🔗http://bit.ly/3VDaK81
Support by edu grants from Eisai…
https://twitter.com/TumorBoardTues/status/1602468719426342913

8/ #TumorBoardTuesday #RenalCell #NephTwitter

🔴#PostTest Q 4️⃣
🗳️ Pt treated w/ combo of cabozantinib + nivolumab develops G3 hypertension. Cabo therapy is held & pt receives anti-hypertensive medication & BP recovers to baseline. At what dose can cabozantinib be restarted?

7/ #TumorBoardTuesday #RenalCell #NephTwitter #MedTwitter #BonumCE
#CME 🔗http://bit.ly/3FamQyu

🔴#PostTest Q3️⃣
🗳️ Pt treated w/ combo of pembrolizumab and lenvatinib for metastatic RCC develops grade 3 diarrhea. How might you diagnose which drug is causing this toxicity?

6/ #TumorBoardTuesday #OncTwitter #RenalCell #NephTwitter #MedTwitter #BonumCE
#CME 🔗http://bit.ly/3FamQyu

🔴#PostTest Q 2️⃣
🗳️ Which of the following is NOT a characteristic of immune-mediated toxicities associated with the use of ICIs?

4/ #TumorBoardTuesday #BonumCE
#RenalCell #NephTwitter #MedTwitter

Let’s revisit efficacy of 🔑Ph3 clin trials:
💎#CLEAR
💎#KEYNOTE426
💎#CheckMate9ER
💎#CheckMate214